Pharmacogenomics

Genizon offers innovative and unique pharmacogenomics services to the drug development industry, leveraging assets and technologies from its disease gene discovery programs. These include:

• High throughput Illumina technology-based SNP genotyping
• GeneSys - Genizon's genetic analysis pipeline for linking genes and biomarkers to drug response
• Genizon's network of more than 900 clinicians

These assets and technologies enable the rapid initiation of PGx trials, significant reduction in trial time, and greater power to identify drug response genes and predictive biomarkers.

Scope of Genizon's Pharmacogenomics Service Offering:

• Recruit participants through Genizon's active clinical network
• Identify responder and non-responder groups or adverse drug response groups
• Perform genome-wide genotyping on individual samples
• Perform genetic analysis using GeneSys
• Identify sets of genetic biomarkers and/or drug response genes
• Confirmatory and validation studies are also available

The benefits of this unique and comprehensive pharmacogenomics offering include:

Phase II/III studies

• Significantly reduce subject recruiting time
• Improve trial design, power & predictability
• Quickly identify responder groups
• Shorten drug development cycle
• Improve new drug approval rates
• Identify poorly performing drugs earlier
• Recover failed drugs

Post-marketing studies

• Enhance safety profile
• Minimize adverse events
• Develop target efficacy group
• Expand current markets
• Differentiate products
• Protect drug franchises